KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the transaction, the chief executive officer owned 369,595 shares in the company, valued at $5,798,945.55. The trade was a 8.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
KalVista Pharmaceuticals Stock Performance
KALV stock traded down $0.99 during midday trading on Friday, reaching $14.52. 2,085,829 shares of the company's stock traded hands, compared to its average volume of 572,060. The company has a 50-day moving average price of $12.57 and a two-hundred day moving average price of $11.26. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.32. The firm has a market capitalization of $725.27 million, a PE ratio of -3.93 and a beta of -0.04.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the company earned ($1.07) EPS. As a group, analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently commented on KALV. HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Jones Trading reaffirmed a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. JMP Securities lifted their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 8th. Leerink Partners lifted their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of "Buy" and a consensus price target of $26.29.
View Our Latest Research Report on KalVista Pharmaceuticals
Institutional Investors Weigh In On KalVista Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its holdings in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares during the period. Rhumbline Advisers increased its holdings in shares of KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock worth $611,000 after purchasing an additional 1,762 shares during the period. Corebridge Financial Inc. increased its holdings in shares of KalVista Pharmaceuticals by 12.7% in the first quarter. Corebridge Financial Inc. now owns 19,094 shares of the specialty pharmaceutical company's stock worth $220,000 after purchasing an additional 2,149 shares during the period. MetLife Investment Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 13.2% in the first quarter. MetLife Investment Management LLC now owns 21,688 shares of the specialty pharmaceutical company's stock worth $250,000 after purchasing an additional 2,536 shares during the period. Finally, AlphaQuest LLC increased its holdings in shares of KalVista Pharmaceuticals by 17.1% in the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after purchasing an additional 2,588 shares during the period.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
